BioAdaptives Launches MyndMed Supplement for Brain Performance

BioAdaptives (OTCMKTS: BDPT) has officially launched MyndMed(TM), a next-generation dietary supplement aimed at boosting memory, focus, and overall brain performance. Following extensive testing with highly positive feedback, the company is ramping up production and distribution to meet anticipated demand starting in November. MyndMed(TM) is formulated with clinically studied ingredients that support cognitive function through short-, mid-, and long-term pathways, promoting alertness, neuroplasticity, and cellular energy balance. The supplement is manufactured in the U.S. in cGMP-certified facilities and undergoes third-party testing for purity. It is available nationwide at www.MyndMed.com.

BioAdaptives, through its ClearMynd division, is dedicated to developing science-driven health and wellness products that enhance cognitive performance, recovery, and enduring brain health. The company's mission is to empower individuals with innovative formulations that improve performance and well-being. This launch represents a significant step in expanding their product line to address the growing demand for cognitive health supplements.

The announcement was disseminated by NetworkNewsWire (NNW), a specialized communications platform that focuses on financial news and content distribution. NNW is part of the Dynamic Brand Portfolio @ IBN, which offers a range of services including press release distribution, editorial syndication to over 5,000 outlets, social media distribution, and corporate communications solutions. NNW helps companies like BioAdaptives reach a wide audience of investors, consumers, and journalists, cutting through information overload to provide recognition and brand awareness.